CADTH Canadian Drug Expert Committee recommendation: Insulin glargine and lixisenatide (Soliqua -- Sanofi-Aventis Canada Inc.) indication : adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus inadequately controlled on basal insulin (less than 60 units daily) alone or in combination with metformin

The CADTH Canadian Drug Expert Committee (CDEC) recommends that insulin glargine and lixisenatide (iGlarLixi) be reimbursed as an adjunct to diet and exercise, with or without metformin, to improve glycemic control in adults with T2DM, if the following condition is met: Drug plan costs for iGlarLixi...

Full description

Bibliographic Details

Corporate Author:	CADTH Canadian Drug Expert Committee
Format:	eBook
Language:	English
Published:	Ottawa (ON) CADTH January 3, 2019, 2019
Edition:	Final
Series:	CADTH common drug review
Subjects:	Insurance, Health, Reimbursement Canada Cost-benefit Analysis Hypoglycemic Agents / Therapeutic Use Diabetes Mellitus, Type 2 / Drug Therapy Hypoglycemic Agents / Economics
Online Access:	https://www.ncbi.nlm.nih.gov/books/NBK541455
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa